Semax is a synthetic heptapeptide derived from the adrenocorticotropic hormone (ACTH) fragment 4-7. Developed at the Institute of Molecular Genetics of the Russian Academy of Sciences, it has been the subject of extensive preclinical research investigating cognitive function, neurotrophic factor expression, and neuroprotection in animal and cell culture models. Semax is structurally related to ACTH but does not exhibit the hormonal (corticosteroid-stimulating) activity of the parent molecule.
ACTH(4-7) Derivative Design
Semax has the sequence Met-Glu-His-Phe-Pro-Gly-Pro, where the first four residues correspond to the ACTH(4-7) fragment and the C-terminal Pro-Gly-Pro tripeptide extension serves to enhance metabolic stability, similar to the design strategy used for Selank. The ACTH(4-7) sequence was identified decades ago as the minimal fragment of ACTH that retains neuroactive properties without stimulating adrenal corticosteroid production. The molecular weight of Semax is approximately 813.9 Daltons.
The Pro-Gly-Pro stabilizing sequence protects the peptide from rapid enzymatic degradation, extending its effective half-life in biological systems. This modification was a key innovation that made Semax practical for research applications requiring sustained exposure in preclinical models.
Cognitive Function Research
Preclinical studies have investigated Semax in several rodent behavioral paradigms used to assess learning and memory, including the Morris water maze, passive avoidance testing, and novel object recognition. In these models, Semax administration has been associated with improved performance on spatial learning tasks, enhanced retention of avoidance conditioning, and increased exploratory behavior toward novel stimuli compared to vehicle-treated controls.
The neurochemical mechanisms underlying these behavioral observations have been investigated through microdialysis, immunohistochemistry, and gene expression studies. Research has reported that Semax modulates acetylcholine, dopamine, and serotonin systems in rodent brain tissue. Studies examining cholinergic pathways have reported increased acetylcholine release in the hippocampus and cortex following Semax administration in rat models.
BDNF and NGF Modulation
A major focus of Semax research has been its effects on neurotrophic factor expression. Brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) are critical molecules for neuronal survival, differentiation, and synaptic plasticity. Multiple preclinical studies have reported that Semax administration in rodent models increases the expression of both BDNF and NGF mRNA in the hippocampus, basal forebrain, and cortex.
In-vitro studies using neuronal cell cultures have corroborated these findings, demonstrating that Semax treatment increases neurotrophic factor secretion in dose-dependent patterns. These observations have generated interest in Semax as a research tool for studying the regulation of neurotrophic factor expression and its downstream effects on neuronal survival and circuit function.
Neuroprotection Studies
Semax has been investigated in several preclinical models of neurological injury. In rodent models of cerebral ischemia induced by middle cerebral artery occlusion, Semax administration was associated with reduced infarct volume and improved neurological deficit scores in treated groups compared to controls. These findings have been attributed to multiple proposed mechanisms, including neurotrophic factor upregulation, anti-inflammatory effects, and modulation of apoptotic pathways.
Additional neuroprotection research has examined Semax in models of oxidative stress-induced neuronal death, excitotoxicity, and neurodegeneration. In-vitro studies using hydrogen peroxide or glutamate-challenged neuronal cultures have reported improved cell viability in Semax-treated groups, accompanied by changes in gene expression patterns related to antioxidant defense and mitochondrial function.
Administration and Handling
Semax is provided as a lyophilized powder for research use. In preclinical studies, intranasal administration has been the most common route, though subcutaneous and intraperitoneal routes have also been employed. The peptide should be stored at negative twenty degrees Celsius in lyophilized form and reconstituted in bacteriostatic water or appropriate buffer prior to use. Reconstituted solutions should be kept at two to eight degrees Celsius and consumed within two to three weeks.
Research Use Disclaimer
Semax is intended exclusively for in-vitro and preclinical research. It is not approved for human therapeutic use by any regulatory authority. All findings discussed in this article are derived from animal models and cell culture systems and should not be extrapolated to human physiology. Researchers must adhere to all institutional and regulatory requirements when incorporating Semax into experimental protocols.